Dana Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Dana Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.81M	Sell	7,719 -678	-8%	-$462K	0.13%	194
2026 Q1	$6.49M	Buy	8,397 +2	+0%	+$1.53K	0.19%	134
2025 Q4	$6.48M	Buy	8,395 +3,082	+58%	+$2.09M	0.19%	129
2025 Q3	$2.99M	Buy	+5,313	New	+$3M	0.09%	235
2021 Q1	–	Sell	-4,898	Closed	-$2.37M	–	334
2020 Q4	$2.37M	Sell	4,898 -3,287	-40%	-$1.77M	0.12%	115
2020 Q3	$4.58M	Sell	8,185 -7,943	-49%	-$4.82M	0.25%	82
2020 Q2	$10.1M	Sell	16,128 -14,387	-47%	-$8.17M	0.54%	67
2020 Q1	$14.9M	Buy	30,515 +29,847	+4,468%	+$12.3M	0.91%	43
2019 Q4	$251K	Buy	+668	New	+$225K	0.01%	271

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Dana Investment Advisors's REGN Position: Q2 2026 in Review

Dana Investment Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 8.1% in Q2 2026, selling an estimated $462K and leaving 7,719 shares worth $4.81M. The position accounts for 0.13% of the portfolio, ranked #194.

Dana Investment Advisors first reported a position in REGN in Q4 2019 and has held it in 9 quarters since. The position peaked at $14.9M in Q1 2020. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Dana Investment Advisors held 7,719 shares of Regeneron Pharmaceuticals worth $4.81M as of Q2 2026.
Dana Investment Advisors sold 678 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $462K.
Regeneron Pharmaceuticals made up 0.13% of Dana Investment Advisors's portfolio in Q2 2026, its #194 holding.
Dana Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 9 quarters since.
Dana Investment Advisors's Regeneron Pharmaceuticals position peaked at $14.9M in Q1 2020.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Dana Investment Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.